Reuters logo
BRIEF-AstraZeneca says U.S. FDA accepts new drug application for Lynparza
March 28, 2017 / 11:07 AM / 6 months ago

BRIEF-AstraZeneca says U.S. FDA accepts new drug application for Lynparza

March 28 (Reuters) - AstraZeneca Plc

* U.S. FDA has accepted company’s new drug application (NDA) for Lynparza (olaparib) tablets

* Granted priority review status with a prescription drug user fee act (PDUFA) set for Q3 2017 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below